Clarus Therapeutics Holdings, Inc.

2022 Q3 Form 10-Q Financial Statement

#000119312522224410 Filed on August 19, 2022

View on sec.gov

Income Statement

Concept 2022 Q3 2022 Q2 2022 Q1

Balance Sheet

Concept 2022 Q3 2022 Q2 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $19.17M $9.137M
YoY Change 86.54% 2128.54%
Cash & Equivalents $19.20M $9.137M
Short-Term Investments
Other Short-Term Assets $4.197M $4.383M
YoY Change 111.44% 2335.0%
Inventory $16.81M $14.93M
Prepaid Expenses $4.197M
Receivables $8.705M $8.005M
Other Receivables $0.00 $0.00
Total Short-Term Assets $48.88M $36.46M
YoY Change 73.01% 6078.81%
LONG-TERM ASSETS
Property, Plant & Equipment $60.00K $67.00K
YoY Change -17.81%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets $60.00K $67.00K
YoY Change -17.81% -99.89%
TOTAL ASSETS
Total Short-Term Assets $48.88M $36.46M
Total Long-Term Assets $60.00K $67.00K
Total Assets $48.94M $36.52M
YoY Change 72.77% -38.35%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.488M $14.06M
YoY Change -36.95% 17470.0%
Accrued Expenses $9.834M $11.43M
YoY Change -10.62% 1871.21%
Deferred Revenue
YoY Change
Short-Term Debt $0.00
YoY Change
Long-Term Debt Due $40.51M $38.49M
YoY Change -21.04%
Total Short-Term Liabilities $61.81M $65.95M
YoY Change -19.53% 9322.0%
LONG-TERM LIABILITIES
Long-Term Debt $0.00
YoY Change
Other Long-Term Liabilities $197.0K $925.0K
YoY Change -98.18% -87.76%
Total Long-Term Liabilities $197.0K $925.0K
YoY Change -99.82% -87.76%
TOTAL LIABILITIES
Total Short-Term Liabilities $61.81M $65.95M
Total Long-Term Liabilities $197.0K $925.0K
Total Liabilities $62.00M $66.88M
YoY Change -66.62% 709.67%
SHAREHOLDERS EQUITY
Retained Earnings -$347.2M
YoY Change
Common Stock $5.000K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$13.06M -$30.36M
YoY Change
Total Liabilities & Shareholders Equity $48.94M $36.52M
YoY Change 72.77% -38.35%

Cashflow Statement

Concept 2022 Q3 2022 Q2 2022 Q1

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Entity Central Index Key
EntityCentralIndexKey
0001817944
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-39802
crxt Conversion Of Convertible Notes Payable In To Series D Redeemable Convertible Preferred Stock
ConversionOfConvertibleNotesPayableInToSeriesDRedeemableConvertiblePreferredStock
3360000
dei Entity Registrant Name
EntityRegistrantName
CLARUS THERAPEUTICS HOLDINGS, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
85-1231852
dei Entity Address Address Line1
EntityAddressAddressLine1
555 Skokie Boulevard
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 340
dei Entity Address City Or Town
EntityAddressCityOrTown
Northbrook
dei Entity Address State Or Province
EntityAddressStateOrProvince
IL
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
60062
dei City Area Code
CityAreaCode
847
dei Local Phone Number
LocalPhoneNumber
562-4300
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
false
dei Entity Shell Company
EntityShellCompany
false
CY2022Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
52020731
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19173000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
26415000
CY2022Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
8705000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6341000
CY2022Q2 us-gaap Inventory Net
InventoryNet
16805000
CY2021Q4 us-gaap Inventory Net
InventoryNet
14214000
CY2022Q2 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4197000
CY2021Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4673000
CY2022Q2 us-gaap Assets Current
AssetsCurrent
48880000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
51643000
CY2022Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
60000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
65000
CY2022Q2 us-gaap Assets
Assets
48940000
CY2021Q4 us-gaap Assets
Assets
51708000
CY2022Q2 us-gaap Notes Payable Current
NotesPayableCurrent
40505000
CY2021Q4 us-gaap Notes Payable Current
NotesPayableCurrent
42269000
CY2022Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
8488000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
13945000
CY2022Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9834000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8261000
CY2022Q2 us-gaap Deferred Revenue
DeferredRevenue
2979000
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
1585000
CY2022Q2 us-gaap Liabilities Current
LiabilitiesCurrent
61806000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
66060000
CY2022Q2 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
197000
CY2021Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
1567000
CY2022Q2 us-gaap Liabilities
Liabilities
62003000
CY2021Q4 us-gaap Liabilities
Liabilities
67627000
crxt Conversion Of Convertible Notes Payable In To Series D Redeemable Convertible Preferred Stock
ConversionOfConvertibleNotesPayableInToSeriesDRedeemableConvertiblePreferredStock
0
CY2022Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2022Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
500000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
125000000
CY2022Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52020731
CY2022Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52020731
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24025817
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24025817
CY2022Q2 us-gaap Common Stock Value
CommonStockValue
5000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2022Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
334151000
CY2021Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
305734000
CY2022Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-347219000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-321655000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-13063000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
-15919000
CY2022Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
48940000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
51708000
CY2022Q2 us-gaap Revenues
Revenues
4050000
CY2021Q2 us-gaap Revenues
Revenues
2779000
us-gaap Revenues
Revenues
8061000
us-gaap Revenues
Revenues
5109000
CY2022Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1160000
CY2021Q2 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
554000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
1823000
us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
921000
CY2022Q2 us-gaap Gross Profit
GrossProfit
2890000
CY2021Q2 us-gaap Gross Profit
GrossProfit
2225000
us-gaap Gross Profit
GrossProfit
6238000
us-gaap Gross Profit
GrossProfit
4188000
CY2022Q2 crxt Sales And Marketing
SalesAndMarketing
6688000
CY2021Q2 crxt Sales And Marketing
SalesAndMarketing
9530000
crxt Sales And Marketing
SalesAndMarketing
17418000
crxt Sales And Marketing
SalesAndMarketing
17467000
CY2022Q2 crxt General And Administrative Expenses
GeneralAndAdministrativeExpenses
5625000
CY2021Q2 crxt General And Administrative Expenses
GeneralAndAdministrativeExpenses
5327000
crxt General And Administrative Expenses
GeneralAndAdministrativeExpenses
10910000
crxt General And Administrative Expenses
GeneralAndAdministrativeExpenses
8932000
CY2022Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1229000
CY2021Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
606000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2110000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1817000
CY2022Q2 us-gaap Operating Expenses
OperatingExpenses
13542000
CY2021Q2 us-gaap Operating Expenses
OperatingExpenses
15463000
us-gaap Operating Expenses
OperatingExpenses
30438000
us-gaap Operating Expenses
OperatingExpenses
28216000
CY2022Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-10652000
CY2021Q2 us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-13238000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-24200000
us-gaap Income Loss From Continuing Operations
IncomeLossFromContinuingOperations
-24028000
CY2022Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-728000
CY2021Q2 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1370000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
CY2022Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
0
CY2021Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
0
us-gaap Investment Income Interest
InvestmentIncomeInterest
1000
us-gaap Investment Income Interest
InvestmentIncomeInterest
0
CY2022Q2 us-gaap Interest Expense
InterestExpense
2020000
CY2021Q2 us-gaap Interest Expense
InterestExpense
4877000
us-gaap Interest Expense
InterestExpense
3985000
us-gaap Interest Expense
InterestExpense
9517000
CY2022Q2 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
-1250000
CY2021Q2 us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
-1250000
us-gaap Litigation Settlement Expense
LitigationSettlementExpense
0
CY2022Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-42000
CY2021Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-4877000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1364000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-9517000
CY2022Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10694000
CY2021Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-18115000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-25564000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-33545000
CY2022Q2 crxt Provision For Income Taxes
ProvisionForIncomeTaxes
0
CY2021Q2 crxt Provision For Income Taxes
ProvisionForIncomeTaxes
0
crxt Provision For Income Taxes
ProvisionForIncomeTaxes
0
crxt Provision For Income Taxes
ProvisionForIncomeTaxes
0
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-10694000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-18115000
us-gaap Net Income Loss
NetIncomeLoss
-25564000
us-gaap Net Income Loss
NetIncomeLoss
-33545000
CY2022Q2 crxt Accretion Of Preferred Stock
AccretionOfPreferredStock
0
CY2021Q2 crxt Accretion Of Preferred Stock
AccretionOfPreferredStock
3798000
crxt Accretion Of Preferred Stock
AccretionOfPreferredStock
0
crxt Accretion Of Preferred Stock
AccretionOfPreferredStock
7737000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-10694000
CY2022Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10694000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-21913000
CY2021Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-21913000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-25564000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-25564000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-41282000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41282000
CY2022Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.24
CY2022Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.24
CY2021Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
CY2021Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.75
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.75
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0
CY2022Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44229097
CY2022Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
44229097
CY2021Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
0
CY2021Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
0
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34271291
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34271291
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
0
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
0
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
432000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-14870000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
-30357000
CY2022Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
27537000
CY2022Q2 us-gaap Share Based Compensation
ShareBasedCompensation
451000
CY2022Q2 us-gaap Profit Loss
ProfitLoss
-10694000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
-13063000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
-325780000
CY2021Q1 crxt Conversion Of Series D Redeemable Convertible Preferred Stock Into Common Stock
ConversionOfSeriesDRedeemableConvertiblePreferredStockIntoCommonStock
11829000
CY2021Q1 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
-3939000
CY2021Q1 us-gaap Share Based Compensation
ShareBasedCompensation
176000
CY2021Q1 us-gaap Profit Loss
ProfitLoss
-15429000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
-333143000
CY2021Q2 us-gaap Stock Issued During Period Value Conversion Of Units
StockIssuedDuringPeriodValueConversionOfUnits
-3798000
CY2021Q2 us-gaap Share Based Compensation
ShareBasedCompensation
177000
CY2021Q2 us-gaap Profit Loss
ProfitLoss
-18115000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
-354879000
us-gaap Net Income Loss
NetIncomeLoss
-25564000
us-gaap Net Income Loss
NetIncomeLoss
-33545000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
-1765000
us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
6392000
crxt Settlement Of Interest With Payment In Kind Note
SettlementOfInterestWithPaymentInKindNote
0
crxt Settlement Of Interest With Payment In Kind Note
SettlementOfInterestWithPaymentInKindNote
3125000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1370000
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
crxt Stock Based Compensation Expense
StockBasedCompensationExpense
883000
crxt Stock Based Compensation Expense
StockBasedCompensationExpense
353000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
14000
us-gaap Depreciation And Amortization
DepreciationAndAmortization
12000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
2364000
us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
1828000
crxt Other Increase Decrease Inventories
OtherIncreaseDecreaseInventories
-2591000
crxt Other Increase Decrease Inventories
OtherIncreaseDecreaseInventories
-3903000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-476000
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
142000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-5457000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
1357000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1574000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
6369000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
1395000
us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-125000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-34769000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-21935000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
10000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
20000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
20000000
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
0
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
5000000
crxt Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
27857000
crxt Proceeds From Issuance Of Common Stock And Warrants Net Of Issuance Cost
ProceedsFromIssuanceOfCommonStockAndWarrantsNetOfIssuanceCost
0
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
320000
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
27537000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
25000000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-7242000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
3045000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
26415000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7233000
CY2022Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
19173000
CY2021Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10278000
us-gaap Interest Paid Net
InterestPaidNet
5750000
us-gaap Interest Paid Net
InterestPaidNet
0
crxt Accretion Of Redeemable Convertible Preferred Stock To Redemption Value Including Dividends On Preferred Stock
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueIncludingDividendsOnPreferredStock
0
crxt Accretion Of Redeemable Convertible Preferred Stock To Redemption Value Including Dividends On Preferred Stock
AccretionOfRedeemableConvertiblePreferredStockToRedemptionValueIncludingDividendsOnPreferredStock
7737000
crxt Conversion Of Series D Redeemable Convertible Preferred Stock Into Common Stock
ConversionOfSeriesDRedeemableConvertiblePreferredStockIntoCommonStock
0
crxt Conversion Of Series D Redeemable Convertible Preferred Stock Into Common Stock
ConversionOfSeriesDRedeemableConvertiblePreferredStockIntoCommonStock
11829000
CY2020Q4 crxt Shares Issued In Initial Public Offering
SharesIssuedInInitialPublicOffering
5750000
CY2020Q4 us-gaap Deferred Offering Costs
DeferredOfferingCosts
3700000
CY2020Q4 us-gaap Payments For Underwriting Expense
PaymentsForUnderwritingExpense
2000000
CY2020Q4 crxt Net Proceeds Of Initial Public Offering
NetProceedsOfInitialPublicOffering
58700000
CY2022Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.1
CY2022Q2 us-gaap Equity Method Investment Ownership Percentage
EquityMethodInvestmentOwnershipPercentage
0.05
CY2022Q2 crxt Purchase Of Common Stock
PurchaseOfCommonStock
1300000
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.8
CY2021Q3 crxt Remaining Additional Capital
RemainingAdditionalCapital
25000000
CY2021Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
2549939
CY2021Q3 crxt Remaining Additional Capital
RemainingAdditionalCapital
25000000
CY2021Q3 crxt Remaining Additional Capital
RemainingAdditionalCapital
25000000
CY2021Q3 crxt Net Proceeds Amount
NetProceedsAmount
17000000
CY2021Q3 crxt Conversions Of Stock Shares Converted
ConversionsOfStockSharesConverted
13431410
CY2021Q3 crxt Conversion Of Stock Conversion Price Per Share
ConversionOfStockConversionPricePerShare
10.2
CY2021Q3 us-gaap Secured Debt Other
SecuredDebtOther
10000000
CY2021Q3 crxt Aggregate Shares Of Common Stock
AggregateSharesOfCommonStock
1500000
CY2021Q3 crxt Common Stock Shares Reallocated To The Senior Secured Noteholders For The Satisfaction Of Debt Related Agreement
CommonStockSharesReallocatedToTheSeniorSecuredNoteholdersForTheSatisfactionOfDebtRelatedAgreement
405000
CY2021Q3 crxt Sponsor Shares
SponsorShares
135000
crxt Number Of Issued Patents
NumberOfIssuedPatents
5
crxt Retained Earning Accumulated Deficit
RetainedEarningAccumulatedDeficit
347200000
CY2022Q2 crxt Working Capital Deficit
WorkingCapitalDeficit
12900000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19200000
crxt Retained Earning Accumulated Deficit
RetainedEarningAccumulatedDeficit
347200000
CY2022Q2 us-gaap Notes Payable Current
NotesPayableCurrent
40500000
CY2022Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19200000
CY2021Q4 crxt Finished Goods Gross
FinishedGoodsGross
14500000
CY2022Q2 us-gaap Inventory Gross
InventoryGross
19277000
CY2021Q4 us-gaap Inventory Gross
InventoryGross
22802000
CY2022Q2 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
2472000
CY2021Q4 us-gaap Inventory Valuation Reserves
InventoryValuationReserves
8588000
CY2022Q2 us-gaap Inventory Net
InventoryNet
16805000
CY2021Q4 us-gaap Inventory Net
InventoryNet
14214000
CY2022Q1 us-gaap Deferred Revenue
DeferredRevenue
1980000
CY2021Q1 us-gaap Deferred Revenue
DeferredRevenue
1094000
CY2021Q4 us-gaap Deferred Revenue
DeferredRevenue
1585000
CY2020Q4 us-gaap Deferred Revenue
DeferredRevenue
1172000
CY2022Q2 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
5049000
CY2021Q2 us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
2733000
us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
9455000
us-gaap Deferred Revenue Additions
DeferredRevenueAdditions
4985000
CY2022Q2 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
4050000
CY2021Q2 us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
2779000
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
8061000
us-gaap Deferred Revenue Revenue Recognized1
DeferredRevenueRevenueRecognized1
5109000
CY2022Q2 us-gaap Deferred Revenue
DeferredRevenue
2979000
CY2021Q2 us-gaap Deferred Revenue
DeferredRevenue
1048000
CY2022Q2 us-gaap Deferred Revenue
DeferredRevenue
2979000
CY2021Q2 us-gaap Deferred Revenue
DeferredRevenue
1048000
CY2022Q2 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
200000
CY2021Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
500000
CY2022Q2 crxt Debt Future Minimum Payments Due In Two Years
DebtFutureMinimumPaymentsDueInTwoYears
14000000
CY2021Q3 crxt Class Of Warrant Or Rights Issued During Period Shares New Issues
ClassOfWarrantOrRightsIssuedDuringPeriodSharesNewIssues
9195000
CY2021Q3 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.5
CY2022Q2 crxt Raw Materials
RawMaterials
6259000
CY2021Q4 crxt Raw Materials
RawMaterials
6850000
CY2022Q2 crxt Work In Process
WorkInProcess
955000
CY2021Q4 crxt Work In Process
WorkInProcess
1452000
CY2022Q2 crxt Finished Goods Gross
FinishedGoodsGross
12063000
CY2022Q2 crxt Selling And Marketing Costs
SellingAndMarketingCosts
7073000
CY2021Q4 crxt Selling And Marketing Costs
SellingAndMarketingCosts
6031000
CY2022Q2 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
1873000
CY2021Q4 us-gaap Employee Related Liabilities Current And Noncurrent
EmployeeRelatedLiabilitiesCurrentAndNoncurrent
2005000
CY2022Q2 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
888000
CY2021Q4 us-gaap Accrued Professional Fees Current And Noncurrent
AccruedProfessionalFeesCurrentAndNoncurrent
225000
CY2022Q2 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
9834000
CY2021Q4 us-gaap Accrued Liabilities Current And Noncurrent
AccruedLiabilitiesCurrentAndNoncurrent
8261000
us-gaap Debt Instrument Maturity Date
DebtInstrumentMaturityDate
2025-03-01
CY2020Q1 us-gaap Debt Instrument Face Amount
DebtInstrumentFaceAmount
50000000
CY2020Q1 us-gaap Proceeds From Debt Net Of Issuance Costs
ProceedsFromDebtNetOfIssuanceCosts
43600000
CY2020Q1 us-gaap Sale Leaseback Transaction Rent Expense
SaleLeasebackTransactionRentExpense
3500000
CY2020Q1 us-gaap Prepaid Interest
PrepaidInterest
2900000
CY2021Q3 us-gaap Debt Instrument Convertible Conversion Price1
DebtInstrumentConvertibleConversionPrice1
10
CY2022Q2 crxt Debt Future Minimum Payments Due In Remainder Of Fiscal Year
DebtFutureMinimumPaymentsDueInRemainderOfFiscalYear
6000000
CY2022Q2 crxt Debt Future Minimum Payments Due In One Year
DebtFutureMinimumPaymentsDueInOneYear
15125000
CY2022Q2 crxt Debt Future Minimum Payments Due In Three Years
DebtFutureMinimumPaymentsDueInThreeYears
8000000
CY2022Q2 us-gaap Long Term Debt Maturing In Years Four And Five
LongTermDebtMaturingInYearsFourAndFive
43125000
us-gaap Royalty Expense
RoyaltyExpense
24200000
CY2022Q2 us-gaap Debt Instrument Annual Principal Payment
DebtInstrumentAnnualPrincipalPayment
43100000
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q3 crxt Shares Issued In Exchange For Cancellation Of Issued And Outstanding Convertible Preferred Stock
SharesIssuedInExchangeForCancellationOfIssuedAndOutstandingConvertiblePreferredStock
4901564
CY2022Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
11.5
CY2022Q2 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
3024194
CY2022Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.1
CY2022Q2 crxt Percentage Of Public Offering Price Per Unit
PercentageOfPublicOfferingPricePerUnit
1.10
CY2022Q2 crxt Number Of Days Restricted To Be Purchased After The Offering
NumberOfDaysRestrictedToBePurchasedAfterTheOffering
P45D
CY2022Q2 us-gaap Warrants And Rights Outstanding Maturity Date
WarrantsAndRightsOutstandingMaturityDate
2022-06-11
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1083550
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.78
CY2021 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P9Y11M12D
CY2021Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
149025
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
1.17
crxt Sharebased Compensation Arrangement By Sharebased Payment Award Options Granted Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsGrantedWeightedAverageRemainingContractualTerm
P9Y9M7D
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
36000
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
4.78
crxt Share Based Compensation By Share Based Award Options Cancelled Or Forfeited Weighted Average Remaining Contractual Term
ShareBasedCompensationByShareBasedAwardOptionsCancelledOrForfeitedWeightedAverageRemainingContractualTerm
P9Y11M12D
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1196757
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.33
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P9Y6M
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding
SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
0
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
0
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0
CY2022Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
1196757
CY2022Q2 crxt Share Based Compensation Arrangement By Share Based Payment Award Options Nonvested Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageExercisePrice
4.33
crxt Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Outstanding Weighted Average Remaining Contractual Term
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOutstandingWeightedAverageRemainingContractualTerm
P9Y6M
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
433420
CY2021Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.78
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
58610
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.17
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
14440
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
4.78
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
477630
CY2022Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
4.34
CY2022Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
451000
CY2021Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
177000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
883000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
353000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P2Y11M8D
us-gaap Lease Cost
LeaseCost
100000
us-gaap Shares Subject To Mandatory Redemption Settlement Terms Description
SharesSubjectToMandatoryRedemptionSettlementTermsDescription
In July 2021, Legacy Clarus and Lipocine entered into a settlement agreement that settled all claims between the parties under a previous patent infringement lawsuit, including a pending interference matter (No. 106,128) and the pending Legacy Clarus counterclaims against Lipocine, and provided for a payment by Lipocine to Legacy Clarus of a $4.0 million settlement fee payable as follows: $2.5 million upfront, $1.0 million within 12 months, and the remainder within two years. The Company recognized the payments as income as theywere received. The Company received payment of $2.5 million of the $4.0 million in July 2021.
CY2022Q2 us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
1300000
us-gaap Gain Loss Related To Litigation Settlement
GainLossRelatedToLitigationSettlement
1300000
CY2021Q2 crxt Consulting Fees
ConsultingFees
100000
crxt Consulting Fees
ConsultingFees
100000
CY2021Q3 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
10000000
us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
43100000
CY2022Q2 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
2000000
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
4000000

Files In Submission

Name View Source Status
0001193125-22-224410-index-headers.html Edgar Link pending
0001193125-22-224410-index.html Edgar Link pending
0001193125-22-224410.txt Edgar Link pending
0001193125-22-224410-xbrl.zip Edgar Link pending
crxt-20220630.xsd Edgar Link pending
d373515d10q.htm Edgar Link pending
d373515dex311.htm Edgar Link pending
d373515dex312.htm Edgar Link pending
d373515dex321.htm Edgar Link pending
d373515dex322.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
crxt-20220630_def.xml Edgar Link unprocessable
crxt-20220630_lab.xml Edgar Link unprocessable
crxt-20220630_pre.xml Edgar Link unprocessable
crxt-20220630_cal.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
d373515d10q_htm.xml Edgar Link completed
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending